Full history for every metric is available with a Kvantra account
Enhabit, Inc. (EHAB)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,078 | 1,107 | 1,071 | 1,046 | 1,035 | 1,060 | 1,065 |
| Operating profit | $m | 64 | 77 | |||||
| Net profit | $m | 75 | 111 | -40 | -80 | -156 | -5 | -3 |
| EPS reported | $ | -0.09 | -0.08 | |||||
| Operating cashflow per share | $ | 1.39 | 1.72 | |||||
| Capex per share | $ | 0.10 | 0.14 | |||||
| FCF per share | $ | 1.30 | 1.58 | |||||
| Free cash flow | $m | 66 | 81 | |||||
| Net debt | $m | 405 | 377 | |||||
| Book value equity | $m | 534 | 554 | |||||
| Book value per share | $ | 10.51 | 10.46 | |||||
| Number of shares | m | 50.8 | 52.9 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.88 | 1.28 | |||||
| P/S LTM | x | 0.44 | 0.66 | |||||
| P/FCF LTM | x | 7.12 | 8.74 | |||||
| EV/EBITDA LTM | x | 15.97 | 17.95 | |||||
| EV/Sales LTM | x | 0.87 | 1.02 | |||||
| Earnings Yield LTM | % | -0.98% | -0.45% | |||||
| FCF Yield | % | 14.05% | 11.44% | |||||
| Quality | ||||||||
| ROE | % | -0.86% | -0.58% | |||||
| ROIC | % | -11.01% | -1.58% | |||||
| Operating margin | % | 6.02% | 7.25% | |||||
| Gross margin | % | 46.92% | 47.93% | |||||
| FCF/Sales | % | 6.21% | 7.60% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +2.44% | +3.16% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | +38.82% | +63.43% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.13 | 0.17 | |||||
| Net Debt/EBITDA | x | 7.88 | 7.10 | |||||
| EBIT/Net interest | x | 1.88 | 2.23 | |||||
| Net debt/market cap | % | 86.40% | 53.34% | |||||
| Net debt/Equity | x | 0.76 | 0.68 | |||||
| Gross debt/equity | x | 0.94 | 0.87 | |||||
Company overview
Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit provides tailored disease-specific plans for individuals with diabetes, congestive heart failure, those recovering from orthopedic surgery or injuries, and patients with respiratory illnesses. Complementing these medical offerings, licensed physical, occupational, and speech therapists deliver vital rehabilitative support. Beyond home health, Enhabit delivers extensive hospice services designed to meet the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. These services encompass pain and symptom control, palliative and dietary counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit maintained a significant operational footprint, with 252 home health agencies and 99 hospice agencies spread across 34 states. Established in 2014 and headquartered in Dallas, Texas, the company was previously known as Encompass Health Home Health Holdings, Inc., officially rebranding to Enhabit, Inc. in March 2022. Enhabit, Inc. began operating as a completely independent entity on July 1, 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Enhabit, Inc. (EHAB)
Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit provides tailored disease-specific plans for individuals with diabetes, congestive heart failure, those recovering from orthopedic surgery or injuries, and patients with respiratory illnesses. Complementing these medical offerings, licensed physical, occupational, and speech therapists deliver vital rehabilitative support. Beyond home health, Enhabit delivers extensive hospice services designed to meet the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. These services encompass pain and symptom control, palliative and dietary counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit maintained a significant operational footprint, with 252 home health agencies and 99 hospice agencies spread across 34 states. Established in 2014 and headquartered in Dallas, Texas, the company was previously known as Encompass Health Home Health Holdings, Inc., officially rebranding to Enhabit, Inc. in March 2022. Enhabit, Inc. began operating as a completely independent entity on July 1, 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free